CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized Study Short-Term Progression of Multiterritorial Subclinical Atherosclerosis Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Long-term effects of intensive glucose lowering on cardiovascular outcomes Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial Negative Risk Markers for Cardiovascular Events in the Elderly Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Expert Opinion03 January 2021

JOURNAL:Eur Heart J. Article Link

The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them

M Nicholls. Keywords: coronay prevention; heart disease

Full Text PDF